[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524929":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":37,"centralContacts":42,"locations":52,"responsibleParty":80,"collaborators":83,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":10,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":106,"minAge":10,"maxAge":10,"enrollmentInfo":107,"targetDuration":110,"studyType":111,"phases":10,"briefSummary":112,"conditions":113,"keywords":10,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Oulu University Hospital","OTHER",[8,14,18,22,26,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Pre-eclampsia risk group",null,"Approximately 300 women will be enrolled into a risk group according to a pre-eclampsia risk calculator.",[13],"Other: Pre-eclampsia screening program",{"label":15,"type":10,"description":16,"interventionNames":17},"PCOS group","Women enrolled into study who fulfill ≥2 Rotterdam criteria. Women with PCOS may be included in risk- or control groups.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Control group","Approximately 300 women in low risk for pre-eclampsia according to a pre-eclampsia risk calculator.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Follow up group","Approximately 2100 women who are not enrolled into risk-, control- or PCOS groups.",[13],{"label":27,"type":10,"description":28,"interventionNames":10},"Children","Mothers and fathers will be asked for permission to follow the child's health information from national registers until the age of 15 years. Approximately 300 children will be recruited to PEPPI-offspring follow up study (including also PCOS offspring).",{"label":30,"type":10,"description":31,"interventionNames":10},"Fathers","The role of fathers in the development of pregnancy complications and on the health of the offspring.",[33],{"type":6,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"Pre-eclampsia screening program","Pregnant women will be devided into risk-, control- and PCOS groups according to first trimester screening program.",[19,23,15,9],[38],{"name":39,"affiliation":40,"role":41},"Jaana Nevalainen, Assoc prof","The Wellbeing Services County of North Ostrobothnia","PRINCIPAL_INVESTIGATOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Jaana E Nevalainen, Assoc prof","CONTACT","+358405801857","jaana.nevalainen@oulu.fi",{"name":49,"role":45,"phone":50,"phoneExt":10,"email":51},"Terhi Piltonen, Professor","+358405008266","terhi.piltonen@oulu.fi",[53],{"facility":40,"status":54,"city":55,"state":10,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Oulu","90100","Finland","FI",{"type":60,"coordinates":61},"Point",[62,63],25.46816,65.01236,{"lat":63,"lon":62},[66,68,69,72,74,76,78],{"name":67,"role":45,"phone":46,"phoneExt":10,"email":47},"Jaana E Nevalainen, Assoc Prof",{"name":49,"role":45,"phone":50,"phoneExt":10,"email":51},{"name":70,"role":71,"phone":10,"phoneExt":10,"email":10},"Marja Ojaniemi, Assoc Prof","SUB_INVESTIGATOR",{"name":73,"role":71,"phone":10,"phoneExt":10,"email":10},"Liisa Laatio, PhD",{"name":75,"role":71,"phone":10,"phoneExt":10,"email":10},"Hilkka Nikkinen, PhD",{"name":77,"role":71,"phone":10,"phoneExt":10,"email":10},"Pekka Pinola, PhD",{"name":79,"role":71,"phone":10,"phoneExt":10,"email":10},"Tiina Kantomaa, MD",{"type":41,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jaana Nevalainen","Associate professor",[84,87,89,91,93,96],{"name":85,"class":86},"PerkinElmer, Inc.","INDUSTRY",{"name":88,"class":86},"Roche Diagnostics GmbH",{"name":90,"class":6},"Academy of Finland",{"name":92,"class":6},"Sigrid Jusélius Foundation",{"name":94,"class":95},"Finnish Medical Foundation","NETWORK",{"name":97,"class":6},"University of Oulu","100524929","peppi-study-identification-of-women-at-risk-for-placental-dysfunction-100524929",false,"NCT06115122","PEPPI Study: Identification of Women at Risk for Placental Dysfunction","PEPPI Study: Identification of Women at Risk for Placental Dysfunction During the First and Third Trimesters of Pregnancy","Mothers\n\nInclusion Criteria for PEPPI-study\n\n* Pregnant (first trimester)\n* Understands Finnish\n* ≥18 years\n* Signed informed consent\n\nExclusion Criteria\n\n* Multiple pregnancy\n* Miscarriage\u002Ftermination of the index pregnancy\n* No first trimester blood sampling\n\nInclusion Criteria for FERPPI-study\n\n* Participates in PEPPI-study (criteria above)\n* Blood samples at first and third trimester of pregnancy\n* Permits blood sampling from the umbilical cord when the baby is born\n\nExclusion Criteria\n\n* No first or third trimester blood sampling\n* No umbilical cord blood sample after baby is born\n\nFathers\n\nInclusion Criteria\n\n* Biological father to the child born for the mother who participated in PEPPI study\n* ≥18 years\n* Signed informed consent\n\nExclusion Criteria\n\n• Does not understand Finnish\n\nChildren\n\nInclusion Criteria for PEPPI-study\n\n* Born to mother who participated in PEPPI study\n* Signed informed consent from parent(s)\n\nExclusion Criteria\n\n• No consent from parent(s)\n\nInclusion Criteria for PEPPI-offspring study • Mother in risk-, control-, or PCOS group during PEPPI-study with ultrasound information at gestational weeks 30-32 or a mother who developed pre-eclampsia during the pregnancy regardless of their study group during PEPPI-study\n\nExclusion Criteria\n\n• Mother\u002Ffather declines participation\n\nInclusion Criteria for FERPPI-study\n\n* Signed informed consent from parent(s)\n* Mother has blood samples taken at first and third trimester (iron status)\n* Child has blood samples taken at birth and at 3 months of age\n\nExclusion Criteria\n\n* No consent from parent(s)\n* No blood samples from mother\n* No blood samples from child",true,"ALL",{"count":108,"type":109},3000,"ESTIMATED","15 Years","OBSERVATIONAL","The main purpose of this study is to evaluate Fetal Medicine Foundation's pre-eclampsia risk calculator using maternal characteristics, first trimester serum placental growth factor (PlGF) and mean arterial pressure (MAP) in a Finnish general population.\n\nCondition or disease: pre-eclampsia, intrauterine growth restriction, polycystic ovary syndrome",[114,115,116,117,118,119,120],"Pre-Eclampsia","Intrauterine Growth Restriction","Polycystic Ovary Syndrome","Iron-deficiency","Cardiovascular Diseases","Hypertensive Disorder of Pregnancy","Proteinuria in Pregnancy","2025-07-31",{"date":123,"type":124},"2025-08-05","ACTUAL",{"date":126,"type":124},"2022-02-15",{"date":128,"type":109},"2041-12-31",{"name":5,"class":6},1]